Evidence map›Paper›PMID 35038051›Full record

ArticleThe AAPS journal2022

Correction to: Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.

Roberto A Abbiati, Michael Pourdehnad, Soraya Carrancio, Daniel W Pierce, Shailaja Kasibhatla, Mark McConnell, Matthew W B Trotter, Remco Loos, Cristina C Santini, Alexander V Ratushny

Open access · bronzeAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in The AAPS journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Roberto A AbbiatiBristol Myers Squibb, Center for Innovation and Translational Research Europe (CITRE), Seville, Spain. roberto.abbiati@bms.com.
Michael PourdehnadBristol Myers Squibb, San Francisco, California, USA.
Soraya CarrancioBristol Myers Squibb, San Diego, California, USA.
Daniel W PierceBristol Myers Squibb, San Diego, California, USA.
Shailaja KasibhatlaBristol Myers Squibb, San Diego, California, USA.
Mark McConnellBristol Myers Squibb, Seattle, Washington, USA.
Matthew W B TrotterBristol Myers Squibb, Center for Innovation and Translational Research Europe (CITRE), Seville, Spain.
Remco LoosBristol Myers Squibb, Center for Innovation and Translational Research Europe (CITRE), Seville, Spain.
Cristina C SantiniRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.
Alexander V RatushnyBristol Myers Squibb, Seattle, Washington, USA. alexander.ratushnyy@bms.com.
Bristol-Myers Squibb (United States) · USRoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35038051
PMCPMC9172776
OpenAlexW4205304887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.